Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Analyst Ratings
Moderate Buy
12 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NTLA Stock 12 Month Forecast
Average Price Target
$21.22
▲(72.24% Upside)
| Highest Price Target$54.00 | Average Price Target$21.22 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Hold
―
Reiterated
11/07/25
Wells Fargo
$17→$12
Hold
-2.60%
Downside
Reiterated
11/07/25
Oppenheimer
$33→$27
Buy
119.16%
Upside
Reiterated
11/07/25
Barclays
$24→$14
Buy
13.64%
Upside
Reiterated
11/07/25
Citizens JMP
$29→$21
Buy
70.45%
Upside
Reiterated
11/07/25
Bank of America Securities
$14
Hold
13.64%
Upside
Reiterated
11/07/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Chardan Capital
$48→$26
Buy
111.04%
Upside
Reiterated
11/06/25
RBC Capital
$14→$9
Hold
-26.95%
Downside
Reiterated
11/06/25
JonesTrading
$25
Buy
102.92%
Upside
Reiterated
11/04/25
Intellia Therapeutics: Buy Rating Backed by MAGNITUDE Trial Resumption and Promising Data ReleasesWe see positive risk-reward skew on NTLA's upcoming updates Our KOL Webinar Date & Nov 5th, 2025 at 12pm ET. Register HERE. KOL Profile: Dr. Carlos Garcia Santos-Gallego is the Director of the ATTR New York. He treats 285 ATTR patients.
H.C. Wainwright
$25→$18
Buy
46.10%
Upside
Reiterated
10/30/25
Mitchell Kapoor Maintains Buy Rating on Intellia Therapeutics Despite Market Overreaction to Phase 3 Trial PauseValuation and Risks. Using an 11% discount rate and 3% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated EV of ~$2.9B. We believe that our discount rate assumption is appropriate, since Intellia’s products are targeting well-known diseases with validated targets and mechanisms. Similarly, we believe that our terminal growth rate is appropriate, as it factors in potential upside from additional shots on goal for Intellia’s pipeline candidates that we do not capture in our period cash flows.
Truist Financial
―
Buy
―
Reiterated
10/28/25
Bernstein
$14→$14.5
Hold
17.69%
Upside
Downgraded
10/28/25
Evercore ISI
$48
Buy
289.61%
Upside
Reiterated
10/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Hold
―
Reiterated
11/07/25
Wells Fargo
$17→$12
Hold
-2.60%
Downside
Reiterated
11/07/25
Oppenheimer
$33→$27
Buy
119.16%
Upside
Reiterated
11/07/25
Barclays
$24→$14
Buy
13.64%
Upside
Reiterated
11/07/25
Citizens JMP
$29→$21
Buy
70.45%
Upside
Reiterated
11/07/25
Bank of America Securities
$14
Hold
13.64%
Upside
Reiterated
11/07/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Chardan Capital
$48→$26
Buy
111.04%
Upside
Reiterated
11/06/25
RBC Capital
$14→$9
Hold
-26.95%
Downside
Reiterated
11/06/25
JonesTrading
$25
Buy
102.92%
Upside
Reiterated
11/04/25
Intellia Therapeutics: Buy Rating Backed by MAGNITUDE Trial Resumption and Promising Data ReleasesWe see positive risk-reward skew on NTLA's upcoming updates Our KOL Webinar Date & Nov 5th, 2025 at 12pm ET. Register HERE. KOL Profile: Dr. Carlos Garcia Santos-Gallego is the Director of the ATTR New York. He treats 285 ATTR patients.
H.C. Wainwright
$25→$18
Buy
46.10%
Upside
Reiterated
10/30/25
Mitchell Kapoor Maintains Buy Rating on Intellia Therapeutics Despite Market Overreaction to Phase 3 Trial PauseValuation and Risks. Using an 11% discount rate and 3% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated EV of ~$2.9B. We believe that our discount rate assumption is appropriate, since Intellia’s products are targeting well-known diseases with validated targets and mechanisms. Similarly, we believe that our terminal growth rate is appropriate, as it factors in potential upside from additional shots on goal for Intellia’s pipeline candidates that we do not capture in our period cash flows.
Truist Financial
―
Buy
―
Reiterated
10/28/25
Bernstein
$14→$14.5
Hold
17.69%
Upside
Downgraded
10/28/25
Evercore ISI
$48
Buy
289.61%
Upside
Reiterated
10/28/25
Best Analysts Covering Intellia Therapeutics
1 Month
xxx
Success Rate
15/37 ratings generated profit
Average Return
+3.15%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.54% of your transactions generating a profit, with an average return of +3.15% per trade.
3 Months
xxx
Success Rate
15/37 ratings generated profit
Average Return
+13.41%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.54% of your transactions generating a profit, with an average return of +13.41% per trade.
1 Year
Success Rate
15/37 ratings generated profit
Average Return
+92.05%
reiterated a buy rating 2 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 40.54% of your transactions generating a profit, with an average return of +92.05% per trade.
2 Years
xxx
Success Rate
12/37 ratings generated profit
Average Return
+73.43%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 32.43% of your transactions generating a profit, with an average return of +73.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NTLA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
26
16
15
23
15
Buy
8
5
8
11
7
Hold
25
19
16
21
16
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
60
40
39
55
38
Each month's total comprises the sum of three months' worth of ratings.
NTLA Financial Forecast
NTLA Stock Forecast FAQ
What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 21.22.
What is NTLA’s upside potential, based on the analysts’ average price target?
Intellia Therapeutics has 72.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NTLA a Buy, Sell or Hold?
Intellia Therapeutics has a consensus rating of Moderate Buy which is based on 12 buy ratings, 10 hold ratings and 0 sell ratings.
What is Intellia Therapeutics’s price target?
The average price target for Intellia Therapeutics is 21.22. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $9.00. The average price target represents 72.24% Increase from the current price of $12.32.
The highest analyst price target is $54.00 ,the lowest forecast is $9.00. The average price target represents 72.24% Increase from the current price of $12.32.
What do analysts say about Intellia Therapeutics?
Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
How can I buy shares of NTLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.